Abstract
Neuroendocrine tumors (NETs) are relatively uncommon. They typically arise in the gastrointestinal tract and lungs, and their incidence seems to be rising. Most patients have advanced disease at the time of diagnosis and many more will relapse after surgery. There is thus a great need for improvements in therapy for advanced neuroendocrine tumors. This article reviews the current therapy for both pancreatic NETs and non-pancreatic gastrointestinal NETs, and discusses recent advances in NET management with an emphasis on targeted therapy.
Keywords: Carcinoid tumors, neuroendocrine tumors, targeted therapy, therapy.
Current Clinical Pharmacology
Title:Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Volume: 10 Issue: 4
Author(s): Thorvardur R. Halfdanarson and Jonathan R. Strosberg
Affiliation:
Keywords: Carcinoid tumors, neuroendocrine tumors, targeted therapy, therapy.
Abstract: Neuroendocrine tumors (NETs) are relatively uncommon. They typically arise in the gastrointestinal tract and lungs, and their incidence seems to be rising. Most patients have advanced disease at the time of diagnosis and many more will relapse after surgery. There is thus a great need for improvements in therapy for advanced neuroendocrine tumors. This article reviews the current therapy for both pancreatic NETs and non-pancreatic gastrointestinal NETs, and discusses recent advances in NET management with an emphasis on targeted therapy.
Export Options
About this article
Cite this article as:
Halfdanarson R. Thorvardur and Strosberg R. Jonathan, Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies, Current Clinical Pharmacology 2015; 10 (4) . https://dx.doi.org/10.2174/1574884710666151020100211
DOI https://dx.doi.org/10.2174/1574884710666151020100211 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Preoperative and Follow up Multi-Detector Row CT Angiography (MDCTA) in the Evaluation of Interrupted Aortic Arch (IAA)
Current Medical Imaging Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Long-term Reproductive and Metabolic Consequences of PCOS
Current Diabetes Reviews Rimonabant for the Treatment of Obesity
Recent Patents on Cardiovascular Drug Discovery Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis
Current Pharmaceutical Design Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews A Dietary Approach for Treating Dyslipidemia and Hyperglycemia
Current Nutrition & Food Science Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Onco-Surgical Management of Colo-Rectal Liver Metastases in Older Patients: A New Frontier in the 3<sup>rd</sup> Millennium
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry